Clinical Trials in the USA / NCT07288320
Recruiting
Phase 2
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
NCT07288320 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Bipolar I DisorderMania
Investigational drug(s) / intervention(s)
NBI-1117568 →Placebo
NBI-1117568: Oral administration
Placebo: Oral administration
Study summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.
Eligibility
Key Inclusion Criteria:
* Participant has a primary diagnosis of bipolar I disorder.
* The participant has had at least 1 prior documented manic episode that required treatment.
* The participant is experiencing an acute manic episode or manic episode with mixed features, with or without psychotic symptoms.
Key Exclusion Criteria:
* Any unstable or poorly controlled medical condition or chronic disease (including history of neurological, hepatic, renal, cardiovascular, gastrointestinal, pulmonary, autoimmune, or endocrine disease that may affect study participation or results), or malignancy within 90 days before the start of screening.
* Primary diagnosis is not bipolar I disorder.
* History of clozapine treatment for treatment-resistant psychosis.
* History of psychiatric hospitalization(s) for ≥30 consecutive days during the 90 days before the start of screening.
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Primary outcome measure(s)
- Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Day 21 — Baseline, Day 21
Trial sites (11)
| Facility | City | Region | Status |
|---|---|---|---|
| Neurocrine Clinical Site | Little Rock | Arkansas | Recruiting |
| Neurocrine Clinical Site | Cerritos | California | Recruiting |
| Neurocrine Clinical Site | Garden Grove | California | Recruiting |
| Neurocrine Clinical Site | San Diego | California | Recruiting |
| Neurocrine Clinical Site | Hollywood | Florida | Recruiting |
| Neurocrine Clinical Site | Atlanta | Georgia | Recruiting |
| Neurocrine Clinical Site | Gaithersburg | Maryland | Recruiting |
| Neurocrine Clinical Site | Marlton | New Jersey | Recruiting |
| Neurocrine Clinical Site | Staten Island | New York | Recruiting |
| Neurocrine Clinical Site | Austin | Texas | Recruiting |
| Neurocrine Clinical Site | Houston | Texas | Recruiting |
More Neurocrine Biosciences trials in the USA
Other trials for the same condition
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07288320 on ClinicalTrials.gov ↗ ← All trials in the USA